share_log

Oppenheimer Maintains Outperform on Keros Therapeutics, Lowers Price Target to $63

Benzinga ·  Dec 16, 2024 13:02  · Ratings

Oppenheimer analyst Andreas Argyrides maintains Keros Therapeutics (NASDAQ:KROS) with a Outperform and lowers the price target from $102 to $63.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 372

Recommended

Write a comment